TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11976834

Group type: EXPERIMENTAL
Intervention: 5-FU with food (20 mg/m(2), orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5-FU in fasted state (20 mg/m(2), orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-FU with food and eniluracil
Number of subjects: 12
Study: 10668624

Group type: EXPERIMENTAL
Intervention: Parental expressed emotion (EE) levels in African American families
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Parental expressed emotion (EE) levels in families with daughters
Number of subjects: 54

Group type: COMPARATOR
Intervention: Parental expressed emotion (EE) levels in families with sons
Number of subjects: 54
Study: 7756663

Group type: EXPERIMENTAL
Intervention: Desferrioxamine B (iron chelator)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Quinine + Placebo
Number of subjects: 81
Study: 2101962

Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.04 mg, p.o.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) (50 mg, i.v.) alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) (50 mg, i.v.) with Clenbuterol (0.04 mg, p.o.)
Number of subjects: 21
Study: 428232

Group type: EXPERIMENTAL
Intervention: Copper T IUD
Number of subjects: 35496
Study: 29886779

Group type: EXPERIMENTAL
Intervention: Intact umbilical cord milking (I‐UCM)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 102
Study: 31651319

Group type: EXPERIMENTAL
Intervention: Treatment for tuberculosis
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Being female
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Age 0-5 years
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Unknown HIV status
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Pulmonary positive case
Number of subjects: 1086
Study: 26483291

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (3 months, 12 weekly sessions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 26260350

Group type: EXPERIMENTAL
Intervention: Police Education Programme (PEP)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Pre-PEP and post-PEP surveys
Number of subjects: 1200
Study: 23233719

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily + Temsirolimus 30 mg daily (5 days every 2 weeks)
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Letrozole + Placebo
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Letrozole + Temsirolimus (in patients ≤ 65 years)
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Letrozole + Placebo (in patients ≤ 65 years)
Number of subjects: 1112
Study: 21891901

Group type: EXPERIMENTAL
Intervention: Sign Grading System
Number of subjects: 50
Study: 19573188

Group type: EXPERIMENTAL
Intervention: Experiential learning
Number of subjects: 210

Group type: COMPARATOR
Intervention: Guided learning
Number of subjects: 210
Study: 17452167

Group type: EXPERIMENTAL
Intervention: VLTS-589 (Del-1)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Poloxamer 188 (control)
Number of subjects: 105
Study: 15188088

Group type: EXPERIMENTAL
Intervention: Slow-stroke massage (M)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control groups (C) - relaxation and perception
Number of subjects: 32
Study: 11570683

Group type: EXPERIMENTAL
Intervention: Liner Bond 2 (self‐etching) (LB2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Liner Bond 2V (self‐etching) (LB2V)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Solid Bond (total etching) (SB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Opti Bond Solo (single component) (OBS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fuji Bond LC (filled) (FBLC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2‐1 (single component) (P&B2‐1)
Number of subjects: 60
Study: 9663726

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. after meals for 2 weeks (group LA)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. + Ecabet sodium 1000 mg b.d. after meals for 2 weeks (group LAE)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lansoprazole + Amoxycillin (group LA)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lansoprazole + Amoxycillin + Ecabet sodium (group LAE)
Number of subjects: 101
Study: 7830161

Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled cradle providing motion and sound stimulation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled cradle
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 38
Study: 2932137

Group type: EXPERIMENTAL
Intervention: 500 micrograms of nebulized ipratropium bromide after 10 mg salbutamol by nebulizer
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10 mg salbutamol (two doses 2 hours apart)
Number of subjects: 24
Study: 30891604

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of EV71 vaccine (dose 1) and HepB on day 1 and EV71 vaccine (dose 2) and MenA on day 30 (SI group)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Administration of doses 1 and 2 of EV71 vaccine on days 1 and 30, respectively (SE1 group)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Administration of HepB and MenA on days 1 and 30, respectively (SE2 group)
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 775
Study: 30421998

Group type: EXPERIMENTAL
Intervention: Self-regulation strategies (MCII) with Fitbit goal of 10,000 steps per day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no self-regulation strategies) with Fitbit goal of 10,000 steps per day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Self-regulation strategies (MCII)
Number of subjects: 85
Study: 26891753

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human G-CSF
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25314773

Group type: EXPERIMENTAL
Intervention: 2 cycles of cytarabine (average dose) in Group 2
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard doses (100 mg/m2) in combination with idarubicin (8‐12 mg/m2) and mitoxantrone (10 mg/m2) in Group 1
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Allo-BMT during first CR
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Unachieved CR after the first cycle
Number of subjects: 243
Study: 22377484

Group type: EXPERIMENTAL
Intervention: Strict glucose control based on insulin (I-group; n=21)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Strict glucose control based on oral agents (O-group; n=18)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Overall group (n=39)
Number of subjects: 39
Study: 20200384

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin < 5.0%
Number of subjects: 11092

Group type: COMPARATOR
Intervention: Glycated hemoglobin 5.0 to < 5.5%
Number of subjects: 11092

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin 5.5 to < 6.0%
Number of subjects: 11092

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin 6.0 to < 6.5%
Number of subjects: 11092

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin ≥ 6.5%
Number of subjects: 11092
Study: 17209215

Group type: EXPERIMENTAL
Intervention: Multivitamin-multimineral supplement with vitamin C, vitamin E, beta-carotene, and zinc (with cupric oxide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle with a diet rich in antioxidants (lutein, zeaxanthin) and n-3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional nutrients as dietary supplements
Number of subjects: 0
Study: 17541671

Group type: EXPERIMENTAL
Intervention: 8-hour interactive BAI training workshop
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lipid management workshop
Number of subjects: 26
Study: 14997933

Group type: EXPERIMENTAL
Intervention: Immunization with amyloid-beta peptide
Number of subjects: 2
Study: 11134690

Group type: EXPERIMENTAL
Intervention: 400-mg caplets of Garcinia cambogia (total dose of 2.4 g/day, 1.2 g/day HCA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Matched placebos
Number of subjects: 89
Study: 8636173

Group type: EXPERIMENTAL
Intervention: Weight-bearing in a below-knee walking plaster
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-weight-bearing with crutches
Number of subjects: 81
Study: 1460157

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 84
Study: 3912959

Group type: EXPERIMENTAL
Intervention: Coeliac plexus block
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pancreaticogastrostomy
Number of subjects: 17
Study: 30630862

Group type: EXPERIMENTAL
Intervention: Azacitidine maintenance (50 mg/m2, subcutaneously, days 1‐5, every 4 weeks) until relapse, for a maximum of 12 cycles (N = 56)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Observation (N = 60)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Azacitidine maintenance
Number of subjects: 116

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 116
Study: 28829514

Group type: EXPERIMENTAL
Intervention: Somatostatin retained enema, conducted twice every day for at least 30 minutes each time, with treatment courses lasting 7 days.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Basic treatment plan (Control group).
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Somatostatin retained enema (Observation group).
Number of subjects: 79
Study: 26173772

Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 IU/month
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 23607709

Group type: EXPERIMENTAL
Intervention: Handheld MPD tester
Number of subjects: 37

Group type: COMPARATOR
Intervention: PUVA panel MPD
Number of subjects: 37
Study: 21302138

Group type: EXPERIMENTAL
Intervention: Rabeprazole 5 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/day
Number of subjects: 22
Study: 19703730

Group type: EXPERIMENTAL
Intervention: Topical ketamine (10% cream) applied to the symptomatic limb
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 17983368

Group type: EXPERIMENTAL
Intervention: Sodium phosphate tablets
Number of subjects: 411

Group type: COMPARATOR
Intervention: Polyethylene glycol plus bisacodyl tablets
Number of subjects: 411
Study: 14695958

Group type: EXPERIMENTAL
Intervention: HIV prevention counseling intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (clients who completed the intervention)
Number of subjects: 32
Study: 11725734

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol alone (25 micrograms every 3 hours for no more than 12 hours)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Combination therapy (transcervical Foley balloon + intravaginal misoprostol)
Number of subjects: 81
Study: 9222185

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8431749

Group type: EXPERIMENTAL
Intervention: Zenoderm (ZM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: DuoDERM E (DE)
Number of subjects: 64
Study: 3126515

Group type: EXPERIMENTAL
Intervention: Ethanol (0.695 g/kg of body weight over a 15‐min period)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethanol placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 6
Study: 31586424

Group type: EXPERIMENTAL
Intervention: Caspofungin (2 mg/kg once daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (1 mg/kg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate
Number of subjects: 49
Study: 29367614

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 105
Study: 26892411

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (B1)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (B2)
Number of subjects: 101
Study: 24916063

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Videolaryngoscopy
Number of subjects: 17
Study: 22946775

Group type: EXPERIMENTAL
Intervention: LMA ProSeal(TM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: i-Gel(TM)
Number of subjects: 51
Study: 21191437

Group type: EXPERIMENTAL
Intervention: Web-based LFQ administration
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Interactive voice response system (IVRS)-based LFQ administration
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Interviewer-based LFQ administration
Number of subjects: 149

Group type: COMPARATOR
Intervention: Paper-based LFQ administration
Number of subjects: 149
Study: 18655988

Group type: EXPERIMENTAL
Intervention: Neocrom Cohesive (sodium hyaluronate 1.4%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healon (sodium hyaluronate 1.0%)
Number of subjects: 29
Study: 16319330

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV), applied 3 h/day, 5 days a week, for 3 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham-NIMV
Number of subjects: 42
Study: 11986591

Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass (LF)
Number of subjects: 23
Study: 9593937

Group type: EXPERIMENTAL
Intervention: EEG recordings during the decision-making task
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mental counting of clock sounds
Number of subjects: 15
Study: 7618770

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (60 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral ibuprofen (800 mg)
Number of subjects: 82
Study: 2677101

Group type: EXPERIMENTAL
Intervention: Low sodium diet (43 mmol/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High sodium diet (175 mmol/day)
Number of subjects: 7
Study: 33053

Group type: EXPERIMENTAL
Intervention: Terfenadine 60, 120 and 240 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 100 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30811290

Group type: EXPERIMENTAL
Intervention: MRI arm
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 360
Study: 27006391

Group type: EXPERIMENTAL
Intervention: Barriers Questionnaire 13 items (BQ-13)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain intensity measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 0
Study: 26303801

Group type: EXPERIMENTAL
Intervention: Elbasvir (5 to 50 mg for genotype 1; 10 to 100 mg for genotype 3) once daily for 5 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23605507

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 21976155

Group type: EXPERIMENTAL
Intervention: Betel nut chewing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control (disguised chewing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure control (no chewing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chewing (general)
Number of subjects: 0
Study: 19364637

Group type: EXPERIMENTAL
Intervention: Short Musculoskeletal Function Assessment Dysfunction Index (SMFA DI)
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Short Form‐36 Physical Component Summary (SF‐36 PCS)
Number of subjects: 1319
Study: 16904441

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation (HoLEP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Open transvesical prostatectomy (OP)
Number of subjects: 63
Study: 14742331

Group type: EXPERIMENTAL
Intervention: Caudal ketamine group (bupivacaine + S(+)-ketamine 0.5 mg x kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: i.v. ketamine group (bupivacaine + S(+)-ketamine 0.5 mg x kg(‐1) i.v.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine group (plain bupivacaine 0.25% 1 ml x kg(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caudal ketamine group
Number of subjects: 60
Study: 11569153

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 107

Group type: COMPARATOR
Intervention: Immobilization (soft collar)
Number of subjects: 107
Study: 9189303

Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study: 1347291

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3884688

Group type: EXPERIMENTAL
Intervention: 100 mcg of albuterol powder
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 mcg of albuterol powder
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mcg of albuterol powder
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29128326

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy Behaviors Training (HBT)
Number of subjects: 80
Study: 28286262

Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (100 mg/kg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 26882812

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 85
Study: 23327664

Group type: EXPERIMENTAL
Intervention: Intervention (model to improve implementation of guidelines)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 32
Study: 22023281

Group type: EXPERIMENTAL
Intervention: Exposure to hostile e‐confederates in chat-room condition
Number of subjects: 134

Group type: COMPARATOR
Intervention: Exposure to benign e‐confederates in chat-room condition
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Aggressive adolescents
Number of subjects: 134
Study: 18334615

Group type: EXPERIMENTAL
Intervention: Hood CPAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional nasal system
Number of subjects: 0
Study: 16547997

Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Imaging (THI)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional Sonography
Number of subjects: 23
Study: 14514229

Group type: EXPERIMENTAL
Intervention: Nonporous polytetrafluoroethylene (NP) membrane
Number of subjects: 24

Group type: COMPARATOR
Intervention: Porous expanded polytetrafluoroethylene (P) membrane
Number of subjects: 24
Study: 11117082

Group type: EXPERIMENTAL
Intervention: Ultrasound markers (non-cardiovascular and cardiovascular)
Number of subjects: 2080

Group type: EXPERIMENTAL
Intervention: Non-cardiovascular markers
Number of subjects: 2080

Group type: EXPERIMENTAL
Intervention: Combination of right‐to‐left chamber disproportion with CNS, NSF, HB and PY
Number of subjects: 2080
Study: 8645387

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (1 mg/kg/day in three divided doses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19
Study: 1464342

Group type: EXPERIMENTAL
Intervention: Ubiquinone (coenzyme Q10) 3 x 33.3 mg/day orally for 4 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2982622

Group type: EXPERIMENTAL
Intervention: 1 g/m2 of cyclophosphamide pretreatment before chemotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard chemotherapy (cyclophosphamide, vincristine, and methotrexate) without pretreatment
Number of subjects: 45
Study: 3527182

Group type: EXPERIMENTAL
Intervention: Pirenzepine dihydrochloride (LS group)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Gefarnate (GF group)
Number of subjects: 233
Study: 31274657

Group type: EXPERIMENTAL
Intervention: Intraoperative adverse events (near misses)
Number of subjects: 175
Study: 31462701

Group type: EXPERIMENTAL
Intervention: Patient-centered report
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard report
Number of subjects: 94
Study: 30074410

Group type: COMPARATOR
Intervention: Method 1 (informed consent documents mailed prior to visit)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Method 2 (informed consent documents provided in person at the visit)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Method 1
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Method 2
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Method 1 and Method 2
Number of subjects: 520
Study: 27575409

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab monotherapy (IVM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravitreal combination (IVC) of dexamethasone implant and ranibizumab
Number of subjects: 40
Study: 26226350

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moclobemide (75mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination of nicotine and moclobemide
Number of subjects: 24
Study: 24183037

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (75 mg clopidogrel + 100 mg aspirin daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin alone (100 mg daily)
Number of subjects: 60
Study: 21427443

Group type: EXPERIMENTAL
Intervention: Folinic acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18819960

Group type: EXPERIMENTAL
Intervention: Weight loss (5% or greater over 6 months)
Number of subjects: 6933

Group type: EXPERIMENTAL
Intervention: Weight loss (annual weight loss exceeding 10%)
Number of subjects: 6933

Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 6933

Group type: COMPARATOR
Intervention: Candesartan treatment
Number of subjects: 6933